Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bupivacaine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : APIM Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Nordic Nanovector and APIM Therapeutics Announce Merger Agreement
Details : ATX-101 is a first-in-class peptide targeting PCNA (Proliferating Cell Nuclear Antigen), a master regulator of cellular responses to stress and in tumour cell evasion from therapy. ATX-101 is currently being evaluated in platinum-sensitive ovarian cancer...
Product Name : ATX-101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 11, 2022
Lead Product(s) : Bupivacaine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : APIM Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Details : 106 patients has been enrolled for PARADIGME, ongoing pivotal Phase 2b trial of Betalutin (177Lu lilotomab satetraxetan) for the treatment of anti-CD20 refractory follicular lymphoma.PARADIGME data to be reported in second half of 2022.
Product Name : Betalutin
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
July 01, 2022
Lead Product(s) : 177-Lu Lilotomab Satetraxetan,Lilotomab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Betalutin® (177Lu Lilotomab Satetraxetan), showed signs of efficacy in this frail, elderly and difficult-to-treat patient population, the independent expert panel reported that the efficacy data are less promising than the data reported from the Phase 2...
Product Name : Betalutin
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
June 21, 2022
Lead Product(s) : 177-Lu Lilotomab Satetraxetan,Lilotomab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 177-Lu Lilotomab Satetraxetan
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Betalutin (177Lu lilotomab satetraxetan), is a next-generation single-dose CD37-directed radioimmunotherapy (RIT) for the treatment of Hodgkin B-cell lymphoma.
Product Name : Betalutin
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
May 07, 2022
Lead Product(s) : 177-Lu Lilotomab Satetraxetan
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 177-Lu DOTA-NNV003,Olaparib
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Humalutin® (177Lu-DOTA-NNV003), acts by inducing potentially cytotoxic DNA breaks in the NHL cells, sensitising these cells to olaparib, which prevents repair of DNA breaks by blocking activity of DNA repair enzymes poly (ADP ribose) polymerase 1 and 2 ...
Product Name : Humalutin
Product Type : Radiolabelled Compounds
Upfront Cash : Inapplicable
March 05, 2022
Lead Product(s) : 177-Lu DOTA-NNV003,Olaparib
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The primary objective of the PARADIGME trials is to determine the effectiveness of Betalutin (177Lu Lilotomab Satetraxetan), a novel single-dose radioimmunotherapy that targets CD37, an antigen found on the surface of tumour cells of Follicular Lymphoma.
Product Name : Betalutin
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
February 06, 2022
Nordic Nanovector to Present at 3rd Targeted Radiopharmaceutical Summit 2021
Details : Betalutin® (177Lu-lilotomab satetraxetan), an anti-CD37 beta-emitting radioimmuno conjugate has shown an encouraging efficacy and safety profile in 3rd line NHL patients who are refractory to anti-CD20-based treatments.
Product Name : Betalutin
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
July 12, 2021
Lead Product(s) : 177-Lu Lilotomab Satetraxetan
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : ICON Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Nordic Nanovector Sees Significant Improvement in Patient Recruitment Rate in PARADIGME
Details : Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL).
Product Name : Betalutin
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
February 18, 2021
Lead Product(s) : 177-Lu Lilotomab Satetraxetan
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : ICON Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 177-Lu Lilotomab Satetraxetan,Rituximab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data from this cohort is expected in H1'2021 and will be analysed alongside the data generated from the first cohort of patients receiving 10 MBq/kg Betalutin®/40mg lilotomab.
Product Name : Betalutin
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
November 19, 2020
Lead Product(s) : 177-Lu Lilotomab Satetraxetan,Rituximab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study found that Betalutin (an anti-CD37 radioimmunoconjugate) acted synergistically with rituximab (anti-CD20 immunotherapy) to suppress tumour growth in a rituximab-resistant xenograft NHL mouse model.
Product Name : Betalutin
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
August 10, 2020